NeoImmuneTech, Inc. (KOSDAQ:950220)

NeoImmuneTech Statistics

Total Valuation

NeoImmuneTech has a market cap or net worth of KRW 55.17 billion. The enterprise value is -4.76 billion.

Market Cap	55.17B
Enterprise Value	-4.76B

Important Dates

The last earnings date was Friday, November 14, 2025.

Earnings Date	Nov 14, 2025
Ex-Dividend Date	n/a

Share Statistics

NeoImmuneTech has 98.87 million shares outstanding. The number of shares has increased by 223.96% in one year.

Current Share Class	n/a
Shares Outstanding	98.87M
Shares Change (YoY)	+223.96%
Shares Change (QoQ)	-88.86%
Owned by Insiders (%)	0.96%
Owned by Institutions (%)	n/a
Float	93.73M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	585.10
PB Ratio	0.84
P/TBV Ratio	0.97
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	0.16
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	0.15

Financial Position

The company has a current ratio of 3.63, with a Debt / Equity ratio of 0.18.

Current Ratio	3.63
Quick Ratio	3.49
Debt / Equity	0.18
Debt / EBITDA	n/a
Debt / FCF	-0.37
Interest Coverage	-38.41

Financial Efficiency

Return on equity (ROE) is -53.36% and return on invested capital (ROIC) is -27.48%.

Return on Equity (ROE)	-53.36%
Return on Assets (ROA)	-21.70%
Return on Invested Capital (ROIC)	-27.48%
Return on Capital Employed (ROCE)	-41.07%
Revenue Per Employee	1.81M
Profits Per Employee	-570.33M
Employee Count	52
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	-139.73M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -50.33% in the last 52 weeks. The beta is 0.54, so NeoImmuneTech's price volatility has been lower than the market average.

Beta (5Y)	0.54
52-Week Price Change	-50.33%
50-Day Moving Average	685.60
200-Day Moving Average	1,038.33
Relative Strength Index (RSI)	47.36
Average Volume (20 Days)	2,304,954

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, NeoImmuneTech had revenue of KRW 94.29 million and -29.66 billion in losses. Loss per share was -92.75.

Revenue	94.29M
Gross Profit	94.29M
Operating Income	-27.89B
Pretax Income	-29.80B
Net Income	-29.66B
EBITDA	-23.93B
EBIT	-27.89B
Loss Per Share	-92.75

Balance Sheet

The company has 71.43 billion in cash and 11.51 billion in debt, giving a net cash position of 59.92 billion or 606.10 per share.

Cash & Cash Equivalents	71.43B
Total Debt	11.51B
Net Cash	59.92B
Net Cash Per Share	606.10
Equity (Book Value)	65.57B
Book Value Per Share	605.13
Working Capital	53.75B

Cash Flow

In the last 12 months, operating cash flow was -30.12 billion and capital expenditures -1.14 billion, giving a free cash flow of -31.26 billion.

Operating Cash Flow	-30.12B
Capital Expenditures	-1.14B
Free Cash Flow	-31.26B
FCF Per Share	-316.18

Margins

Gross Margin	100.00%
Operating Margin	-29,578.65%
Pretax Margin	-31,601.83%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

NeoImmuneTech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-223.96%
Shareholder Yield	-223.96%
Earnings Yield	-53.76%
FCF Yield	-56.66%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

NeoImmuneTech has an Altman Z-Score of -2.51. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-2.51
Piotroski F-Score	n/a